Angiotech Pharmaceuticals, Inc., of Vancouver, Canada, has been given clearance to market the Hemo-Stream chronic dialysis catheter, the first device of its kind specifically designed for over-the-wire delivery.


Benefits for patients include higher flow rates enabled by the catheter’s triple lumen design, reduced potential for air embolism or bleeding, ease of placement, and decreased procedural steps and time versus competition.

Continue Reading


“With over 500,000 end-stage renal disease patients in the U.S., Angiotech is focused on the development of innovative dialysis care products that improve the treatment options available to hemodialysis patients and vascular surgeons,” said William Hunter, MD, MSc, president and CEO of Angiotech.